Type 2 Diabetes Clinical Trial and Competitive Landscape Analysis: 200+ Key Companies Shaping the Future of Type 2 Diabetes Therapeutics Space | DelveInsight

The type 2 diabetes competitive landscape report delivers important insights into approved as well as ongoing research on 200+ pipeline type 2 diabetes drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

New York, USA, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Type 2 Diabetes Clinical Trial and Competitive Landscape Analysis: 200+ Key Companies Shaping the Future of Type 2 Diabetes Therapeutics Space | DelveInsight 

The type 2 diabetes competitive landscape report delivers important insights into approved as well as ongoing research on 200+ pipeline type 2 diabetes drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s Type 2 Diabetes Competitive Landscape and Clinical Trial Analysis 2026 report provides comprehensive global coverage of approved and pipeline type 2 diabetes therapies across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the type 2 diabetes therapeutics domain.

Key Takeaways from the Type 2 Diabetes Pipeline Report

• DelveInsight’s type 2 diabetes competitive landscape and clinical trial analysis report presents a robust market with over 170+ active players developing more than 200+ pipeline Type 2 Diabetes therapies. 
• Key type 2 diabetes companies, such as Guangdong Raynovent Biotech Co., Ltd, Innovent Biologics, AstraZeneca, Genprex, Inc., Sciwind Biosciences, Neurodon, Autotelic Bio, Qilu Pharmaceutical, Ascletis Pharma, Jiangsu Hengrui Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Alnylam Pharmaceuticals, Corxel Pharmaceuticals, Sun Pharmaceutical Industries, Amgen, Hanmi Pharmaceutical Company Limited, Antag Therapeutics, Rezubio Pharmaceuticals Co., Ltd., Gan&Lee Pharmaceuticals, Atrogi, Sparrow Pharmaceuticals, Genexine, Biomea Fusion, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Housey Healthcare, Regend Therapeutics, and others, are evaluating new type 2 diabetes drugs to improve the treatment landscape.
• Promising pipeline type 2 diabetes therapies, such as RAY1225, IBI3032, Elecoglipron, GPX-002, XW014, NRDN-101, ATB-101, QLG1091, ASC30, HRS-7535, TQF3250, ALN-4324, CX11, GL0034, AMG 127, HM15275, AT673, RZ-629, GZR18, ATR-258, Clofutriben, GX-G6, Icovamenib, HDM1002, HP-211, REGEND003, and others, are under different phases of Type 2 Diabetes clinical trials.
• Approximately 60+ type 2 diabetes medications are in the late stage of development, whereas 90+ drugs are in the mid and early stages of development.
• Key MoAs under development include Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists, Amylin receptor agonists, GRB14 protein expression inhibitors, RNA interference, Sarcoplasmic reticulum calcium-transporting ATPase stimulants, and others.

Request a sample and discover the recent developments in type 2 diabetes treatment @ https://www.delveinsight.com/report-store/type-2-diabetes-competitive-landscape-and-clinical-trial-analysis

What is Type 2 Diabetes?

Type 2 diabetes is a chronic metabolic disorder characterized by persistently elevated blood glucose levels due to insulin resistance and, over time, inadequate insulin production by the pancreas. Insulin is a hormone that helps glucose move from the bloodstream into cells, where it is used for energy. In people with type 2 diabetes, cells become less responsive to insulin, causing glucose to accumulate in the blood. The condition is commonly associated with factors such as obesity, physical inactivity, unhealthy dietary patterns, aging, and genetic predisposition. Type 2 diabetes can develop gradually and may remain undiagnosed for years, but prolonged high blood glucose can increase the risk of complications affecting the cardiovascular system, kidneys, eyes, nerves, and other organs. Management typically involves lifestyle modifications, including a healthy diet and regular physical activity, along with glucose-lowering medications and, in some cases, insulin therapy.

To know more about business development licensing obesity type 2 diabetes named therapy, visit @ New Drug Treatment for Type 2 Diabetes 

Approved Type 2 Diabetes Drug Profile Analysis

FOUNDAYO: Eli Lilly

Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly for the treatment of type 2 diabetes. By activating GLP-1 receptors, it promotes glucose-dependent insulin secretion, reduces glucagon release, and delays gastric emptying, thereby supporting improved glycemic control. Unlike injectable GLP-1 therapies, orforglipron is administered orally and does not require injections or fasting around dosing. In August 2026, the UK MHRA authorized orforglipron for adults with inadequately controlled type 2 diabetes, making the UK the first European country to approve the therapy for this indication.

OZEMPIC: Novo Nordisk

OZEMPIC (semaglutide), developed by Novo Nordisk, is a once-weekly GLP-1 receptor agonist indicated for the treatment of adults with type 2 diabetes. It helps improve glycemic control by stimulating glucose-dependent insulin secretion and suppressing glucagon release, while also contributing to weight reduction. OZEMPIC is approved as a monotherapy for patients who cannot use metformin and as an add-on therapy to other antidiabetic medications. The FDA approved OZEMPIC for the treatment of T2D in December 2017, followed by European Commission approval in February 2018.

Find out more about intravenous treatment for type 2 diabetes @ New Medicine for Type 2 Diabetes

A snapshot of the Pipeline Type 2 Diabetes Drugs mentioned in the report:

Drug Name	Company	Phase	MoA	RoA
RAY1225	Guangdong Raynovent Biotech Co., Ltd	III	Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists	SC
CagriSema	Novo Nordisk	III	Amylin receptor agonists; Glucagon-like peptide-1 receptor agonists	SC
ALN-4324	Alnylam Pharmaceuticals	II	GRB14 protein expression inhibitors; RNA interference	SC
TQF3250	Chia Tai Tianqing Pharmaceutical Group	I	Glucagon-like peptide-1 receptor agonists	Oral
IBI3032	Innovent Biologics	I	Glucagon-like peptide-1 receptor agonists	Oral
NRDN-101	Neurodon	Preclinical	Sarcoplasmic reticulum calcium-transporting ATPase stimulants	Oral

Learn more about advances in type 2 diabetes treatment @ Type 2 Diabetes Clinical Trials

Arunima Dabral, Assistant Project Manager of Competitive Intelligence and Consulting at DelveInsight, said that the Type 2 diabetes treatment landscape continues to evolve, supported by the growing adoption of therapies offering improved glycemic control, convenient dosing, and additional metabolic benefits. The increasing use of GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, and newer insulin formulations is expected to strengthen treatment options across different patient populations. At the same time, established therapies such as metformin, DPP-4 inhibitors, SGLT2 inhibitors, and insulin remain important components of routine disease management. Continued clinical development, regulatory approvals, and expanding evidence on cardiovascular and renal outcomes are likely to further shape treatment preferences and competition within the Type 2 diabetes market.

Recent Developments in the Type 2 Diabetes Treatment Space

• In September 2026, Eli Lilly and Company received US FDA approval for Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The approval makes Onswik a once-weekly basal insulin option for adults with T2D.
• In September 2026, Novo Nordisk announced topline Phase III results from the REIMAGINE 5 trial of CagriSema, a once-weekly fixed-dose combination of cagrilintide and semaglutide, in adults with type 2 diabetes. CagriSema achieved superior weight loss versus tirzepatide 5 mg while demonstrating non-inferior HbA1c reduction at Week 60.
• In August 2026, Novo Nordisk announced the nationwide launch of Awiqli® (insulin icodec-abae) injection 700 units/mL, the first once-weekly basal insulin approved as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults living with type 2 diabetes, following the US Food and Drug Administration (FDA) approval earlier this year.
• In August 2026, Structure Therapeutics announced that the first patients have been dosed in the Phase III ACCOMPLISH program, which includes two clinical trials evaluating aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist.
• In July 2026, Kailera Therapeutics, Inc. announced positive topline data from two additional Phase III clinical trials of oral small molecule GLP-1 receptor agonist HRS-7535 (also known as KAI-7535) conducted by Hengrui Pharma.
• In June 2026, positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an oral small molecule GLP-1 receptor agonist (GLP-1 RA), were presented at the 2026 Scientific Sessions of the American Diabetes Association (ADA) and simultaneously published in The Lancet. AstraZeneca is advancing elecoglipron into an extensive Phase III programme in obesity and type 2 diabetes, including cardiovascular and kidney outcome trials.
• In May 2026, Genprex, Inc. announced that its research collaborators presented positive preclinical data on the Company’s diabetes gene therapy drug candidate at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The collaborators presented preclinical data demonstrating that the diabetes gene therapy (Pdx1/MafA gene therapy, PM or GPX-002) can reverse hyperglycemia in Type 2 diabetic (T2D) mouse models.
• In March 2026, Eli Lilly and Company announced positive topline results from TRANSCEND-T2D-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise.
• In February 2026, Novo Nordisk announced headline results from REIMAGINE 2, a Phase III trial from the global REIMAGINE clinical trial programme. CagriSema demonstrated both superior HbA1c reduction and weight loss at week 68 versus semaglutide, across all tested doses in the trial.
• In February 2026, Autotelic Bio announced that it has entered into an exclusive license and technology transfer agreement with Aché Laboratórios Farmacêuticos S.A. for ATB-101, the world’s first combination therapy designed to simultaneously treat hypertension and diabetes. Under the agreement, Aché has secured the exclusive rights to manufacture and commercialize ATB-101 in the Brazilian market.
• In February 2026, Alnylam Pharmaceuticals, Inc. reported that the company has initiated a Phase II clinical trial of ALN-4324, an investigational RNAi therapeutic targeting GRB14 for type 2 diabetes mellitus.

Scope of the Type 2 Diabetes Pipeline Report 

• Coverage: Global 
• Key Type 2 Diabetes Companies: Guangdong Raynovent Biotech Co., Ltd, Innovent Biologics, AstraZeneca, Genprex, Inc., Sciwind Biosciences, Neurodon, Autotelic Bio, Qilu Pharmaceutical, Ascletis Pharma, Jiangsu Hengrui Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Alnylam Pharmaceuticals, Corxel Pharmaceuticals, Sun Pharmaceutical Industries, Amgen, Hanmi Pharmaceutical Company Limited, Antag Therapeutics, Rezubio Pharmaceuticals Co., Ltd., Gan&Lee Pharmaceuticals, Atrogi, Sparrow Pharmaceuticals, Genexine, Biomea Fusion, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Housey Healthcare, Regend Therapeutics, and others.
• Key Pipeline Type 2 Diabetes Therapies: RAY1225, IBI3032, Elecoglipron, GPX-002, XW014, NRDN-101, ATB-101, QLG1091, ASC30, HRS-7535, TQF3250, ALN-4324, CX11, GL0034, AMG 127, HM15275, AT673, RZ-629, GZR18, ATR-258, Clofutriben, GX-G6, Icovamenib, HDM1002, HP-211, REGEND003, and others.

Dive deep into rich insights for the type 2 diabetes drug pipeline 2026 clinical trials; visit @ Type 2 Diabetes Drugs

Table of Contents

1.	Type 2 Diabetes Pipeline Report Introduction
2.	Type 2 Diabetes Pipeline Report Executive Summary
3.	Type 2 Diabetes Pipeline: Overview
4.	Type 2 Diabetes Marketed Drugs
4.1.	FOUNDAYO: Eli Lilly
5.	Type 2 Diabetes Clinical Trial Therapeutics
6.	Type 2 Diabetes Pipeline: Late-Stage Products (Pre-registration)
7.	Type 2 Diabetes Pipeline: Late-Stage Products (Phase III)
7.1.	RAY1225: Guangdong Raynovent Biotech Co., Ltd
8.	Type 2 Diabetes Pipeline: Mid-Stage Products (Phase II)
8.1.	ALN-432: Alnylam Pharmaceuticals
9.	Type 2 Diabetes Pipeline: Early-Stage Products (Phase I)
9.1.	TQF3250: Chia Tai Tianqing Pharmaceutical Group
10.	Type 2 Diabetes Pipeline: Preclinical and Discovery Stage Products
11.	Type 2 Diabetes Pipeline Therapeutics Assessment
12.	Inactive Products in the Type 2 Diabetes Pipeline
13.	Company-University Collaborations (Licensing/Partnering) Analysis
14.	Unmet Needs
15.	Type 2 Diabetes Market Drivers and Barriers
16.	Appendix

For further information on when will cagrisema launch in the US for obesity and type 2 diabetes, reach out @ Type 2 Diabetes Drug Treatment

Related Reports

Type 2 Diabetes Market 

Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., and others.

Type 2 Diabetes Pipeline

Type 2 Diabetes Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc.,  and others.

Diabetes Market

Diabetes Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc., and others.

GLP-1 Agonists Market

GLP-1 Agonists Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key GLP-1 agonists companies, including Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, Amgen, Viking Therapeutics, Regor Therapeutics, Carmot Therapeutics, Roche, GlaxoSmithKline, Sanofi, and others.

Obesity Market 

Obesity Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obesity companies, including Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679